Madrigal Pharmaceuticals, Inc.

NasdaqGS MDGL

Madrigal Pharmaceuticals, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -668.54%

Madrigal Pharmaceuticals, Inc. Net Income Margin is -668.54% for the Trailing 12 Months (TTM) ending September 30, 2024. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGS: MDGL

Madrigal Pharmaceuticals, Inc.

CEO	Mr. William J. Sibold
IPO Date	Feb. 6, 2007
Location	United States
Headquarters	Four Tower Bridge
Employees	376
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Key trends

Past 5 years